人生长激素基因逆转录病毒载体的构建及其对3T3和ES细胞的转化与表达

为了研究生长激素基因在异源细胞中的表达,构建了携带人生长激素基因（ｈＧＨ）的逆转录病毒载体ｐＩＮＳ－ＧＨ,并将其导入小鼠成纤维细胞３Ｔ３和小鼠胚胎干细胞（ＥＳ细胞）ＣＣＥ中。ｐＩＮＳ－ＧＨ转化３Ｔ３细胞,获得了高效表达的克隆,即用放射免疫法检测到克隆培养基中有大量的人生长激素蛋白富积,如ＧＨＳＮＣ２０,富积率高达３７８４ｎｇ／ｍｌ,而且外源基因的整合很稳定。不同的３Ｔ３转化克隆的表达率有显著的差异,Ｓｏｕｔｈｅｒｎ杂交的结果表明,这种差异与外源基因整合的拷贝数无关。ｐＩＮＳ－ＧＨ转化ＣＣＥ细胞没有获得明显表达的克隆,而且外源基因的整合也不稳定。转化的ＥＳ细胞克隆总ＤＮＡ的Ｓｏｕｔｈｅｒｎ杂交结果表明,ｈＧＨ基因的确整合到细胞基因组中。目前尚未发现明显的外源ＤＮＡ重排的迹象。     

特异性向肝细胞表达和复制的EB病毒载体系统的组建

发展了一种高效的、能将推带外源基因的质粒型ＥＢ病毒载体特异性导入肝细胞表达的方法,将ＥＢ病毒复制子载体ｐＤＲ２经改造得到携带外源基因的ｐＥＢｌｕｃ质粒,将ｐＥＢｌｕｃ与人工制备的、既保留了ＤＮＡ结合活性又有为为肝细胞受体识别并内在化的半乳糖基化组蛋白的ｆｌ组分结合形成ｐＥＢｌｕｃ－半乳糖基化组蛋白复合物。该复合物通过脱唾液酸糖蛋白受体介导的内吞进入肝并表达。ｐＥＢｌｕｃ质粒在细胞内能稳定存在并自主     

靶向性DNA甲基化酶在pET32a原核表达载体中的表达和鉴定

目的:在pET32a原核表达载体中表达融合myc-6his标签的靶向性甲基化酶B1-3a并进行鉴定。方法:以含有B1-3a基因的pcDNA4.0-B1-3a-myc-6his质粒为模板,通过PCR的方法扩增获得融合有myc-6his标签序列的目的区段B1-3a,然后克隆入表达载体pET32a;以SDS-PAGE和Western blot方法对表达产物进行鉴定。结果:表达产物中在分子量43kD左右可见与目的蛋白分子量相符的条带,该条带可被6his标签单克隆抗体特异识别。结论:正确构建了靶向性甲基化酶B1-3a的原核表达载体,靶向性甲基化酶能够在pET32a中成功表达。     

带红色荧光蛋白靶向线粒体载体的构建与表达

选取由核表达的线粒体蛋白细胞色素C氧化亚单位Ⅷ（COX8）的前导序列为靶序列,从人胚胎肺成纤维细胞中扩增出COX8的前导序列,插入到pcDNA3．1／myc—HisA中,并将pDsRED1-n1中的红色荧光蛋白序列RFP克隆至COX8的下游,形成融合蛋白。在脂质体的介导下,将重组载体转染至肿瘤细胞中,在荧光显微镜下观察其在细胞内的表达及分布情况。构建的靶向线粒体的载体以及以红色荧光蛋白为报告基因的靶向线粒体的载体,经酶切、DNA序列测定,结果表明构建正确。将pcDNAmito—RFP转染到HeLa细胞的线粒体中,16h即可见散在荧光,72h达高峰,第10d开始减弱。以上结果表明成功构建了以红色荧光蛋白为报告基因的线粒体靶向的特异表达载体,在靶序列的引导下将红色荧光蛋白输入到线粒体中,为进一步对线粒体疾病的基因治疗研究提供了重要工具。     

肿瘤靶向治疗的新型细胞载体

肿瘤靶向性病毒作为一种特殊的肿瘤治疗药物和基因治疗载体近年来已得到长足发展,许多高效、靶向性病毒载体已被相继研究开发,但仍不能满足临床上肿瘤靶向治疗的需要,如何将这些靶向病毒准确而高效地运输到肿瘤病变部位仍然未得到充分解决.细胞因子诱导杀伤细胞(cytokine-inducedkillercells,CIK)作为肿瘤的细胞治疗方法之一已成功地在临床上得到了广泛应用.最近科学家使用CIK细胞作为病毒运载工具,成功地将病毒运载到肿瘤组织部位并显示出高效的抗肿瘤作用,该方法为病毒运输定位于肿瘤病变部位找到了突破口,实验资料显示其具有潜在的应用价值.     

逆转录病毒载体介导的LacZ基因在NIH-3T3细胞中的稳定表达

精原干细胞(SSCs)介导的转基因技术很可能成为制作转基因动物及治疗雄性不育的一条新途径。为了研究逆转录病毒载体介导法转染体外培养SSCs的可行性,用脂质体介导法将携带LacZ基因的重组逆转录病毒载体pLNCL导入包装细胞PA317,用含G418的培养液筛选得到5株稳定转染的产毒细胞。收集这些克隆的产毒上清,过滤后进行倍比稀释,用NIH-3T3细胞通过X-gal染色测定其浓缩前病毒滴度。结果显示,PA3173培养上清中病毒的浓缩前滴度最高,达1.1×103CFU/mL。再将筛选到的稳定转染的NIH-3T3细胞培养至单层,进行X-gal染色检测β-半乳糖苷酶的表达。结果显示,大多数稳定转染的NIH-3T3细胞均为X-gal ,表明这些细胞成功表达了目的基因LacZ。本研究结果为后期工作中用该载体感染体外培养SSCs奠定了基础。     

中国人肥胖基因真核表达载体的构建

为研究肥胖（ｏｂｅｓｉｔｙ）的病因及肥胖基因（ｏｂ）的表达与调控,根据文献报道的ｈｏｂ序列设计引物,经ＲＴ－ＰＣＲ扩增中国人的ｏｂ基因（包括信号肽在内的ｃＤＮＡ全长５４０ｂｐ）,ＰＣＲ产物采用Ｔ－Ａ克隆法首先连接到克隆载体ｐＵＣ１１９,然后定向转移到经改造的真核表达载体ｐＳＶ－β－ｌａｃＺ,酶谱分析表达克隆基因为的人肥胖基因。     

外源基因的靶向细胞表达

使外源基因在特定组织细胞中进行表达主要采用两方：一是使用靶向基因载体，这种载体可识别特定组织细胞膜上的一些分子，并与之结合，然后再将外源基因带入细胞中表达；另一种方式是使用组织细胞专一的启动子，来驱动外源基因在该细胞中的特异性表达。     

人神经元素3基因重组逆转录病毒表达载体的构建及其包装细胞株的建立

为构建表达人神经元素3基因(neurogenin 3,ngn3)的重组逆转录病毒载体,建立稳定表达ngn3的包装细胞株,本研究以流产人胎儿胰腺组织为材料,通过RT-PCR方法克隆出人ngn3基因,将其连接到pMD18-T载体上并测序,结果表明,测序得到的基因序列与发表的人ngn3基因序列(GenBank Accession No.BC126468)完全一致。将EcoRI和HpaI双酶切后的基因片段构建到pMSCV-neo逆转录病毒载体中,酶切鉴定结果表明,pMSCV-ngn3重组逆转录病毒载体构建成功。脂质体法将pMSCV-ngn3重组载体导入PT67包装细胞,G418筛选后,对得到的细胞株进行RT-PCR和免疫组化检测,结果显示,该细胞株在mRNA水平和蛋白水平均稳定表达Ngn3;收集该细胞株的培养上清液,进行RT-PCR检测及电镜观察,结果表明,该细胞株将导入的重组逆转录病毒载体pMSCV-ngn3包装成了具有感染性的病毒颗粒,并将其释放到了培养上清液中。以上结果表明PT67-ngn3包装细胞株建立成功。该细胞株的成功建立,为下一步将ngn3基因应用于提高人胎儿胰腺祖细胞诱导分化效率方面的研究奠定了基础。     

基因治疗所用的逆转录病毒载体系统

基因治疗所用的逆转录病毒载体系统徐铿,陈诗书（上海第二医科大学生物化学教研组,２０００２５）关键词基因治疗,逆转录病毒载体,包装细胞八十年代初发展的以逆转录病毒为基础的基因转移系统对今天基因治疗的实现起了关键性的作用。目前近５０个基因治疗计划绝大部分...     

表达猴免疫缺陷病毒Env蛋白的重组鸡痘病毒的构建和筛选

目的:构建并筛选表达猴免疫缺陷病毒(SIV)Env蛋白的重组鸡痘病毒(FPV),并对其进行鉴定。方法:设计引物,通过PCR技术扩增SIV env基因,将其连接到pMD18-T载体上,测序正确后将其克隆入本实验室自行构建的FPV穿梭载体pTKET中,获得重组质粒pTKET-SIV env,然后将其与FPV282E4株共转染原代鸡胚成纤维细胞进行同源重组,以增强型绿色荧光蛋白为筛选标记,通过噬斑筛选获得重组病毒,应用PCR、RT-PCR、Western印迹对重组病毒进行鉴定和遗传稳定性分析。结果:通过10次噬斑筛选,PCR检测表明目的基因已整合到重组FPV基因组中,RT-PCR、Western印迹结果表明SIV Env蛋白在感染细胞内表达且具有抗原性;连续传代20次,PCR、RT-PCR、Western印迹均能检测到外源基因的整合、转录和表达,且未能扩增出FPV-TK基因,表明重组病毒遗传稳定性良好,且病毒已经纯化。结论:获得表达SIV Env蛋白的重组FPV,为进一步免疫试验研究奠定了基础。     

Roles of the interactions between Env and Gag proteins in the HIV-1 replication cycle

The Env and Gag proteins of HIV-1 are the two major structural proteins of this retrovirus. The interactions between Env and Gag proteins and their regulation in HIV-1 are required for several steps of the replication cycle, involving not only virus assembly, specifically Env incorporation, but also entry steps after virus maturation. A large number of host factors and certain membrane microdomains appear to engage both in transport/trafficking of Env and/or Gag proteins, and in the interactions of these two proteins. The present review briefly summarizes our current knowledge regarding the roles of the interactions between Env and Gag proteins in the virus replication cycle.     

Exosomal sorting of the cytoplasmic domain of bovine leukemia virus TM Env protein

Exosomes are small membrane vesicles that are released into the extracellular compartment as a consequence of fusion of multivesicular endosomes with the plasma membrane. To unravel the molecular basis of protein sorting into exosomes, we have made a chimeric protein containing the cytosolic domain of the transmembrane subunit of the viral Env protein of BLV and the ectodomain of CD8 (CDTM-BLV-CD8). When expressed in K562 cells known to constitutively secrete exosomes, the chimera was found to be very efficiently targeted to the released vesicles. Very interestingly, the cytosolic domain of the Env protein contains peptide motifs potentially recognized by components of the ESCRT machinery that could be related to chimera sorting into the vesicles. Then, quantifying the chimera secretion, we investigated the site of exosome biogenesis in K562 cells using a pharmacological approach. We present different arguments indicating that CDTM-BLV-CD8-containing exosomes are likely formed from a recycling endosomal/TGN compartment.     

Characterization of BIV Env core: implication for mechanism of BIV-mediated cell fusion

Entry of lentiviruses, such as human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV), requires folding of two heptad repeat regions (HR1 and HR2) of gp41 into a trimer-of-hairpins, which subsequently brings virus and cell membrane into fusion. This motif is a generalized feature of viral fusion proteins and has been exploited in generating antiviral fusion agents. In the present paper, we report structural characters of Env protein from another lentivirus, bovine immunodeficiency virus (BIV), which contributes to a good animal model of HIV. BIV HR1 and HR2 regions are predicted by two different programs and expressed separately or conjointly in Escherichia coli. Biochemical and biophysical analyses show that the predicted HRs of BIV Env can form a stable trimer-of-hairpins or six-helix bundle just like that formed by feline immunodeficiency virus Env. Cell fusion assay demonstrates that the HR2 peptide of BIV can efficiently inhibit the virus-mediated cell fusion.     

构建表达Flag-GPI的重组乙型肝炎病毒载体

乙型肝炎病毒(hepatitis B virus,HBV)是小型的嗜肝DNA病毒,能够特异性地感染人肝实质细胞。HBV的易感性可以归于多个方面,包括细胞表面的受体以及细胞内的蛋白或其他因子,目前对HBV易感性的了解还有待深入。本课题利用课题组原有的HBV 5c3c载体和糖基磷脂酰肌醇(glycosylphosphatidylinositol,GPI)的特性,构建了重组HBV载体5c3c-CD59-Flag-GPI和5c3cT-Flag-GPI,转染Huh7细胞后可以将Flag标签锚定在细胞膜上,且可利用Flag抗体通过流式细胞术对其进行分选。在回补HBV包膜蛋白的情况下,5c3cT-Flag-GPI能包装形成完整的重组HBV颗粒。本研究为后续优化重组HBV的包装效率,进而为HBV易感性研究提供工具并奠定基础。     

乙型肝炎病毒多聚酶末端蛋白的结构和功能研究

乙肝病毒蛋白结构和功能是当前研究乙肝病毒的热点之一。HBV多聚酶的末端蛋白在病毒复制过程中起重要作用,主要包括前基因组RNA包装和DNA合成的蛋白引发等,并可抑制细胞对干扰素的反应。本文综述了乙肝病毒多聚酶末端蛋白的结构和功能,还比较了乙肝病毒与逆转录病毒多聚酶结构和功能的异同。     

A human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effect

Hepatitis B virus (HBV) produces large (L), middle (M), and small (S) envelope proteins, alternatively referred to as hepatitis B surface antigen (HBsAg). Currently, yeast-derived S protein serves as the preventive vaccine, while hepatitis B immune globulin (HBIG) concentrated from pooled plasma of vaccine recipients is employed for post-exposure prophylaxis. However, only a small proportion of the antibodies in HBIG are HBV specific. In the present study, a human monoclonal anti-S antibody (G12) was developed, produced under GLP conditions, and subjected to a panel of functional assays. In vitro results demonstrated high affinity of G12 for the S protein (K_D = 7.56 nM). It reacted with envelope proteins of all 7 HBV genotypes tested (A-F, H) by immunofluorescent staining, and more than 97% of HBsAg-positive patient serum samples by enzyme-linked immunosorbent assay. G12 recognized a conformational epitope, although the exact sequence remains unknown. Strikingly, G12 was at least 1,000-fold more potent than HBIG in neutralizing HBV infectivity in both HepaRG cell line and HepG2 cells reconstituted with the HBV receptor. In a transgenic mouse model of HBV persistence, a single peritoneal injection of G12 markedly diminished serum HBsAg titers in all 7 mice, which was sustained for the observation period of 144 d in mice with low pre-treatment levels. While the therapeutic potential of G12 warrants further investigation using a large number of animals, G12 is a potent neutralizing human monoclonal antibody and a promising candidate to replace or supplement HBIG in the prevention of HBV infection.